Outcome by MRD2 response. (A) At 36 months, CIR was estimated at 22% (95% CI, 16-32) in patients who achieved a 3-log MRD2 reduction vs 54% (95% CI, 39-69) in those who did not (SHR= 0.27 [95% CI, 0.15-0.49]; P < .001 by cause-specific hazard Cox model). (B) At 36 months, RFS was estimated at 73% (95% CI, 64-81) in patients who achieved a 3-log MRD2 reduction vs 44% (95% CI, 29-58) in those who did not (HR= 0.34 [95% CI, 0.19-0.59]; P < .001, log-rank test). (C) At 36 months, OS from CR was estimated at 90% (95% CI, 83-94) in patients who achieved a 3-log MRD2 reduction vs 71% (95% CI, 51-85) in those who did not (HR= 0.43 [95% CI, 0.17-1.08]; P = .066, log-rank test).